FDA Brief

Warning letters Drugs

FDA warning letter to

Empower Clinic Services, LLC dba Empower Pharma

High riskIssued Apr 2, 2025Posted Apr 22, 2025Center for Drug Evaluation and Research (CDER)

FDA warns Empower Pharma over sterile drug manufacturing deficiencies, labeling, and unapproved compounded drugs after August 2024 inspection.

What happened

FDA inspected Empower Pharma's Houston facility from August 1 to August 28, 2024, and issued a Form FDA 483 (inspection observation list). Investigators found sterile drug products made under insanitary conditions, with inadequate responses to microbial contamination in the ISO 5 aseptic area, inadequate dynamic smoke studies, inadequate environmental monitoring, and inadequate investigations; the company recalled Pyridoxine HCl Injection Solution, 100 mg/mL, lot 609763 on September 5, 2024, for lack of sterility assurance. FDA also found missing 503B container labeling information and said the compounded drugs were unapproved new drugs and misbranded.

What FDA found

  1. FDA found sterile drugs were made under insanitary conditions: microbial contamination in the high-cleanliness ISO 5 aseptic area was not adequately evaluated or corrected, and smoke studies did not show unidirectional airflow under dynamic conditions.

    FDCA section 501(a)(2)(A) [21 U.S.C. 351(a)(2)(A)]
  2. The company did not establish and follow written procedures to prevent microbiological contamination of sterile drugs, including validation of aseptic and sterilization processes.

    21 CFR 211.113(b)
  3. The company did not thoroughly investigate unexplained discrepancies or batch failures, whether or not the batch had been distributed.

    21 CFR 211.192
  4. The company lacked adequate systems for maintaining equipment used to control aseptic conditions and for monitoring environmental conditions in aseptic processing areas.

    21 CFR 211.42(c)(10)(vi) and (iv)
  5. The company lacked written production and process control procedures to assure identity, strength, quality, and purity.

    21 CFR 211.100(a)
  6. The compounded drugs lacked required 503B container labeling information, including adverse-event reporting and directions for use, and FDA said they were unapproved new drugs and misbranded.

    FDCA sections 503B(a)(10), 505(a), and 502(f)(1)

What FDA wants

FDA asks the company to notify it in writing within 15 working days of specific steps taken to address the violations, with explanations and supporting documentation to prevent recurrence. FDA also strongly recommends a comprehensive assessment of operations, especially aseptic processing, by a third-party consultant with sterile drug manufacturing expertise.

Who should pay attention

  • health systems and clinics buying 503B compounded sterile drugs
  • other outsourcing facilities making sterile injectables
  • clinicians and patients receiving compounded injectables or pellets

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. SCA Pharmaceuticals, LLC

    SCA Pharmaceuticals' sterile compounded drugs were made under unsanitary conditions with serious manufacturing violations, FDA says.

    High risk
  2. Pine Pharmaceuticals, LLC

    FDA cited outsourcing facility Pine Pharmaceuticals in Tonawanda, NY, for insanitary sterile compounding conditions and CGMP failures after a November 2025 inspection.

    High risk
  3. Fagron BV

    FDA warns Fagron's Canton, MA sterile compounding site over airflow, cleaning and investigation failures, prompting a recall.

    High risk
  4. RC Outsourcing, LLC

    FDA warned outsourcing facility RC Outsourcing of Lowellville, Ohio, that its sterile drugs were made under insanitary conditions that risk contamination.

    High risk